MLTX logo

MLTX Cash From Operations

Annual CFO

-$116.59 M
-$73.81 M-172.54%

December 31, 2024


Summary


Performance

MLTX Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherMLTXcash flowmetrics:

Quarterly CFO

-$48.47 M
-$23.20 M-91.79%

December 31, 2024


Summary


Performance

MLTX Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherMLTXcash flowmetrics:

TTM CFO

-$116.59 M
-$36.13 M-44.90%

December 31, 2024


Summary


Performance

MLTX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherMLTXcash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

MLTX Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-172.5%-91.8%-44.9%
3 y3 years--437.1%-129.8%
5 y5 years--437.1%-129.8%

MLTX Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-172.5%at low-437.1%at low-721.9%at low
5 y5-year-172.5%at low-437.1%at low-721.9%at low
alltimeall time-172.5%at low-437.1%at low-721.9%at low

MoonLake Immunotherapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Dec 2024
-$116.59 M(+172.5%)
-$48.47 M(+91.8%)
-$116.59 M(+44.9%)
Sep 2024
-
-$25.27 M(-9.4%)
-$80.46 M(+24.9%)
Jun 2024
-
-$27.89 M(+86.6%)
-$64.43 M(+32.3%)
Mar 2024
-
-$14.95 M(+21.1%)
-$48.70 M(+13.8%)
Dec 2023
-$42.78 M
-$12.34 M(+33.4%)
-$42.78 M(+1.8%)
Sep 2023
-
-$9.25 M(-23.9%)
-$42.03 M(-0.2%)
DateAnnualQuarterlyTTM
Jun 2023
-
-$12.16 M(+34.7%)
-$42.13 M(-17.0%)
Mar 2023
-
-$9.02 M(-22.2%)
-$50.73 M(-9.2%)
Dec 2022
-$55.89 M
-$11.60 M(+24.0%)
-$55.89 M(+26.2%)
Sep 2022
-
-$9.35 M(-55.0%)
-$44.30 M(+26.8%)
Jun 2022
-
-$20.76 M(+46.3%)
-$34.95 M(+146.3%)
Mar 2022
-
-$14.19 M
-$14.19 M

FAQ

  • What is MoonLake Immunotherapeutics annual cash flow from operations?
  • What is the all time high annual CFO for MoonLake Immunotherapeutics?
  • What is MoonLake Immunotherapeutics annual CFO year-on-year change?
  • What is MoonLake Immunotherapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for MoonLake Immunotherapeutics?
  • What is MoonLake Immunotherapeutics quarterly CFO year-on-year change?
  • What is MoonLake Immunotherapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for MoonLake Immunotherapeutics?
  • What is MoonLake Immunotherapeutics TTM CFO year-on-year change?

What is MoonLake Immunotherapeutics annual cash flow from operations?

The current annual CFO of MLTX is -$116.59 M

What is the all time high annual CFO for MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics all-time high annual cash flow from operations is -$42.78 M

What is MoonLake Immunotherapeutics annual CFO year-on-year change?

Over the past year, MLTX annual cash flow from operations has changed by -$73.81 M (-172.54%)

What is MoonLake Immunotherapeutics quarterly cash flow from operations?

The current quarterly CFO of MLTX is -$48.47 M

What is the all time high quarterly CFO for MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics all-time high quarterly cash flow from operations is -$9.02 M

What is MoonLake Immunotherapeutics quarterly CFO year-on-year change?

Over the past year, MLTX quarterly cash flow from operations has changed by -$23.20 M (-91.79%)

What is MoonLake Immunotherapeutics TTM cash flow from operations?

The current TTM CFO of MLTX is -$116.59 M

What is the all time high TTM CFO for MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics all-time high TTM cash flow from operations is -$14.19 M

What is MoonLake Immunotherapeutics TTM CFO year-on-year change?

Over the past year, MLTX TTM cash flow from operations has changed by -$36.13 M (-44.90%)